CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 1,559 shares at $5.96 ($9,292)
- 4 Planned sale Chief Operating Officer sold 1,558 shares at $6.28 ($9,777)
- 4 Open-market sale Director sold 22,682 shares at $8.00 ($181,456)
- 4 Open-market sale SVP, Finance & Accounting sold 4,949 shares at $7.87 ($38,958)
- 4 Open-market sale Chief Medical Officer sold 4,963 shares at $7.87 ($39,068)
- 4 Open-market sale Chief Legal Officer sold 7,281 shares at $7.87 ($57,315)
- 4 Open-market sale Chief Operating Officer sold 1,817 shares at $7.87 ($14,303)
- 4 Open-market sale Chief Scientific Officer sold 2,166 shares at $7.87 ($17,051)
- 4 Open-market sale Chief Commercial Officer sold 1,583 shares at $7.87 ($12,461)
- 4 Grant or award Chief Medical Officer acquired 46,250 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award SVP, Finance & Accounting acquired 42,500 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 46,250 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 46,250 shares (grant or award)
Page 4 of 14 · 277 filings